Q1 2026 Bactiguard Holding AB Earnings Call Transcript
Key Points
- Bactiguard Holding AB (OSTO:BACTI B) delivered continued profitability with an adjusted EBITDA of SEK 4.9 million.
- Increased sales of Bactiguard-coated products across collaborations, with BD initiating sales of Bactiguard-coated Foley catheters in parts of Europe.
- The company maintained a high level of engagement in strategic therapeutic areas, including orthopedics, vascular access, cardiology, neurology, and urology.
- Solid performance in the wound management portfolio, with Hydrocyn Aqua being a key driver.
- Continued investment in regulatory-related activities to support existing partners and future collaborations.
- Reported revenues were lower compared to the same quarter last year, with a 16% decrease excluding currency effects.
- Net sales decreased by 17% excluding currency effects, with a notable decline in BD revenues due to timing effects.
- Operating result for Q1 amounted to minus SEK 7.2 million, compared to SEK 2.6 million in the previous year.
- Total cash flow for the period was negative, driven by changes in working capital.
- The company faced challenges with lower shipments of concentrate to BD, affecting reported revenues for the quarter.
Welcome to the Bactiguard Q1 2026 report presentation. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to the speakers, CEO Christine Lind and CFO Patrick Bach. Please go ahead.
Thank you, operator, and welcome, everyone, to Bactiguard's presentation of the first quarter of 2026.
Patrick and I will go through the presentation together today. I will start with an overview of the quarter and our strategic progress, and Patrick will then walk you through our financials in more detail. We will, of course, open up for questions at the end.
The title of today's presentation is Building Momentum Through Partnerships Regulatory Progress, and Organizational Strength, and that reflects how we view this quarter, not driven by a single event, but by continued execution across several
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
